Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00110253 · ClinicalTrials.gov registry record · Phase 3

Duration of Skin Numbing Effect Created by the S-Caine™ Peel

A Phase 3 study of Pain, sponsored by ZARS Pharma.

Completed
Registry status
Phase 3
Development phase
40
Enrollment target
1
Study location

NCT00110253 is a Phase 3 study of Pain that has completed, run by ZARS Pharma. The registered enrollment target is 40 participants, below the 304-participant average among 374 other Pain trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00110253, a Phase 3 study of Pain, has completed, sponsored by ZARS Pharma.

COMPLETED
Registry status
Phase 3
Development phase
40 participants
Enrollment target
1
Study location

Study Summary

S-Caine™ Peel (lidocaine 7% and tetracaine 7% cream) is a new skin numbing cream made of lidocaine and tetracaine. The purpose of this study is to evaluate and measure the length of time the S-Caine Peel numbs the skin, when applied for 30 and 60 minutes.

Conditions Studied

Interventions

  • DRUG S-Caine™ Peel (lidocaine and tetracaine cream 7%/7%)

Study Locations (1)

California

  • Radiant Research - San Diego

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2005-06
Est. Completion 2005-06
Phase Phase 3

Sponsor

ZARS Pharma

23 total trials

What the Registry Record Tells You About NCT00110253

The ClinicalTrials.gov registry entry for NCT00110253 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 304-participant average among 374 other Pain trials with a reported enrollment target (87% lower). The listed sponsor is ZARS Pharma, which has 23 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Pain appearing as the primary indexed condition, and to 1 intervention - of which S-Caine™ Peel (lidocaine and tetracaine cream 7%/7%) is the first listed.

NCT00110253 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT00110253 about?

NCT00110253 is a clinical study titled "Duration of Skin Numbing Effect Created by the S-Caine™ Peel". S-Caine™ Peel (lidocaine 7% and tetracaine 7% cream) is a new skin numbing cream made of lidocaine and tetracaine. The purpose of this study is to evaluate and measure the length of time the S-Caine Peel numbs the skin, when applied for 30 and 60 minutes.

What is the current status of trial NCT00110253?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 40 participants. The study started on 2005-06. Estimated completion is 2005-06.

What conditions does trial NCT00110253 study?

This clinical trial studies the following conditions: Pain.

What interventions are being tested in trial NCT00110253?

The interventions under investigation include: S-Caine™ Peel (lidocaine and tetracaine cream 7%/7%) (DRUG).

Who is sponsoring clinical trial NCT00110253?

This trial is sponsored by ZARS Pharma, which has 23 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00110253 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Pain

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.